# A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment

> **NCT06668805** · PHASE2 · RECRUITING · sponsor: **BioMarin Pharmaceutical** · enrollment: 30 (estimated)

## Conditions studied

- Noonan Syndrome

## Interventions

- **DRUG:** Vosoritide Injection

## Key facts

- **NCT ID:** NCT06668805
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-22
- **Primary completion:** 2027-03
- **Final completion:** 2041-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06668805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06668805, "A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT06668805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*